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OBJECTIVE — Fetuin-A is an inhibitor of vascular calciﬁcation and a mediator of insulin
resistance.Thisstudyevaluatedtheassociationofplasmafetuin-Aandperipheralarterialdisease
(PAD).
RESEARCH DESIGN AND METHODS — A total of 738 individuals with type 2 dia-
betes(meanage58.7years,37.1%female)withoutknowncardiovascularorkidneydiseasewere
included in this cross-sectional analysis.
RESULTS — SubjectswithPADhadasigniﬁcantlylowerfetuin-A(264.3vs.293.4ng/dl,P
0.001). In multivariable analysis, a 1-SD decrease in fetuin-A increased the odds of PAD (odds
ratio 1.6, P  0.02). Subgroup analysis revealed an increased odds even in subjects with
glomerular ﬁltration rate 80 (odds ratio 1.9, P  0.05) or high-sensitivity C-reactive protein
3 mg/dl (odds ratio 2.7, P  0.002).
CONCLUSIONS — Lower circulating fetuin-A is associated with PAD in type 2 diabetes
beyond traditional and novel cardiovascular risk factors. Our ﬁndings suggest a potentially
unique role for fetuin-A deﬁciency as a biomarker of PAD in patients with type 2 diabetes.
Diabetes Care 33:408–410, 2010
I
ndividualswithtype2diabeteshavean
increasedriskforinfra-inguinalarterial
involvement and microvascular dis-
ease and a higher tendency to develop in-
timal atherosclerotic calciﬁcation as well
asmedialarterialcalciﬁcation(1).Despite
advances in the understanding of the
pathophysiology of atherosclerosis, how-
ever, limited data are available on the de-
terminants of the distinct patterns of
peripheral arterial disease (PAD) ob-
served in type 2 diabetes.
Based on the relationship of fetuin-A
deﬁciency with peripheral vascular calci-
ﬁcation in experimental models (2,3), we
hypothesized that low fetuin-A levels in
type 2 diabetes are associated with PAD
independent of the presence of kidney
disease or cardiovascular disease (CVD).
RESEARCH DESIGN AND
METHODS— The Penn Diabetes
Heart Study (PDHS) is an ongoing, cross-
sectional study of individuals with type 2
diabetes (aged 35–75 years) without clin-
ical evidence of CVD (myocardial in-
farction, coronary revascularization or
angiographic disease, positive stress test,
clinical peripheral arterial disease or pe-
ripheral arterial revascularization, stroke,
or transient ischemic attack). Subjects
with type 1 diabetes and creatinine 2.5
mg/dl are excluded. The University of
Pennsylvania Institutional Review Board
approved the study protocol, and all sub-
jects gave written informed consent (4).
Evaluated parameters
Theankle-brachialindex(ABI)wascalcu-
lated by dividing the average of the ankle
pressures by the highest brachial pres-
sure. An ABI 0.9 in either leg was used
to deﬁne PAD. Participants with an ABI
1.4 (n  13) reﬂecting noncompress-
ible arteries were excluded (5). Each sub-
ject had the estimated glomerular
ﬁltration rate (eGFR) calculated based on
the abbreviated Modiﬁcation of Diet in
Renal Disease Study equation (6). Plasma
levels of fetuin-A (4.3 and 10.2%, respec-
tively,intra-assayandinter-assaycoefﬁcient
of variation) were measured by enzyme-
linked immunosorbent assay (Biovendor
Laboratory Medicine, Modrice, Czech Re-
public). High-sensitivity C-reactive protein
(hsCRP) was measured by immunoturbidi-
metric assay (Wako, Osaka, Japan).
Statistical analysis
Categoricalvariableswerecomparedwith
an 
2 test and/or Fisher’s exact test. Stu-
dent’s t test was used for normal contin-
uous variables and the Kruskal-Wallis
for nonnormal distributed variables. All
nonnormal distributed variables were
log-transformedfortheanalysis.Theas-
sociation between a 1-SD change in fe-
tuin-A and PAD was examined using
unadjustedandmultivariableadjustedlo-
gistic regression models as described in
Table 1. A P  0.05 was considered sta-
tistically signiﬁcant. Analyses were per-
formed on Stata 10.0 software (Stata,
College Station, TX).
RESULTS— Among 738 subjects in
the study sample, PAD prevalence was
5.1%,themeanagewas58.79.3years,
37.1% were female, 63.2% were Cauca-
sians, and 32.1% were African Ameri-
cans. The median fetuin-A level was
292.4 ng/ml (interquartile range 115.5).
Individuals with PAD had a signiﬁcantly
lower fetuin-A level compared with indi-
viduals without PAD (269.3 vs. 293.4,
P  0.001). PAD subjects were older and
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icans. No signiﬁcant differences were
noted in other cardiovascular risk factors,
metabolicsyndrome,kidneyfunction,in-
ﬂammation, BMI, serum albumin (the
only surrogate marker of liver function
collected on the PDHS), or medication
use. Fetuin-A levels decreased consis-
tently(Pfortrend0.02)acrossABIclin-
ically relevant cut points (0.7, 0.7–0.9,
0.9–1.1, and 1.1–1.4) (7) (see Supple-
mental Fig. 1 in the online appendix
[available at http://care.diabetesjournals.
org/cgi/content/full/dc09-1541/DC1]).
The odds of PAD were signiﬁcantly
increasedforeachSDdecreaseinfetuin-A
(odds ratio 1.6 [95% CI 1.1–2.3], P 
0.001)andtheassociationpersistedinin-
cremental models that adjusted fully for
age,sex,race,kidneyfunction,cardiovas-
cular risk factors, medication use, and
hsCRP (1.6 [1.05–82.5], P  0.03) (Ta-
ble 1). A similar trend was noted among
subjectswitheGFR80ml min
1 1.73
m
1 (1.9 [1.0–3.4], P  0.05), suggest-
ing that our ﬁndings were not con-
founded by the presence of moderate
kidneydisease.Finally,inafullyadjusted
subgroup analysis, participants with
hsCRP levels 3 mg/dl (n  460) had
higher odds of PAD (2.6 [1.4–5.0], P 
0.002), whereas subjects with high
hsCRPlevels(3mg/dl;n234)didnot
(0.82 [0.4–1.6], P  0.59).
CONCLUSIONS — Low levels of fe-
tuin-A have been linked to medial arte-
rial calciﬁcation and ﬂow limiting aortic
stenosis in humans (8,9). In this study,
we demonstrate that lower levels of fe-
tuin-A are associated with PAD in sub-
jects with type 2 diabetes. To our
knowledge, this is the ﬁrst study to re-
port such a relationship in the absence
of advanced kidney disease or prevalent
CVD. Notably, in analysis stratiﬁed by
theCentersforDiseaseControlandPre-
vention/American Heart Association–
deﬁned hsCRP risk strata (10), fetuin-A
conferredincreasedoddsofPADinsub-
jects with hsCRP 3 mg/dl and also in
participants with interleukin (IL)-6 lev-
els below the median (data not shown).
This is consistent with studies reporting
an increased CVD risk mortality with
fetuin-A deﬁciency independent of
hsCRP and IL-6 (11) and points to a
unique role for this negative acute-
phase protein as a biomarker of PAD
beyond traditional and novel cardiovas-
cular risk factors.
Remarkably,animalmodelsappearto
track with our clinical observations. In
mice lacking the fetuin-A gene, the aorta
was found to be spared of calciﬁcation
andﬁbrosis,whereasperipheralvesselsin
the skin and kidney showed evidence of
extensive calciﬁcation (2), and the small
arteryinvolvementprecededtherenalim-
pairment (3). However, in the absence of
direct imaging data, we are unable to de-
ﬁne the type of vascular phenotype (inti-
mal calciﬁcation or medial calciﬁcation)
that account for the observed association.
An ABI of 0.9 is 95% sensitive and 99%
speciﬁcforastenoticlesion(50%)(12).
Therefore,weassumethatsomedegreeof
eccentric atherosclerotic calciﬁcation
contributes to the association observed
while acknowledging that multiple types
of vascular calciﬁcation may coexist in
type 2 diabetes (13).
Nonalcoholic liver disease and other
phenotypes related to insulin resistance,
including type 2 diabetes (14), are associ-
ated with higher levels of fetuin-A (15).
We controlled for most potential con-
founding factors and found no attenua-
tion of the inverse association of fetuin-A
with PAD. In particular, because of this
inverse relationship, a signiﬁcant con-
founding effect was not expected by any
condition associated with high fetuin-A
levels. Finally, our study is limited by
cross-sectional design, which limits
causal inferences.
Insummary,lowplasmafetuin-Alev-
els are associated with PAD in type 2 dia-
betes independent of traditional and
contemporary risk factors. Our ﬁndings
suggest a unique role for fetuin-A deﬁ-
ciency as a biomarker of PAD in the set-
ting of type 2 diabetes.
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